[go: up one dir, main page]

NO20053918L - Aminosyrer med affinitet for alfa-2-delta-proteinet. - Google Patents

Aminosyrer med affinitet for alfa-2-delta-proteinet.

Info

Publication number
NO20053918L
NO20053918L NO20053918A NO20053918A NO20053918L NO 20053918 L NO20053918 L NO 20053918L NO 20053918 A NO20053918 A NO 20053918A NO 20053918 A NO20053918 A NO 20053918A NO 20053918 L NO20053918 L NO 20053918L
Authority
NO
Norway
Prior art keywords
amino acids
affinity
alpha
delta protein
compounds
Prior art date
Application number
NO20053918A
Other languages
English (en)
Inventor
David Juergen Wustrow
Andrew John Thorpe
Nancy Sue Barta
Jacob Bradley Schwarz
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28675482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20053918(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20053918L publication Critical patent/NO20053918L/no
Application filed by Warner Lambert Co filed Critical Warner Lambert Co

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)

Abstract

Det beskrives visse ;5-aminosyrer som binder til a2^-subenheten av en kalsiumkanal. Forbindelsene og deres farmasøytisk akseptable salter finner anvendelse ved behandling av et antall psykiattiske, smerte- og andre hdelser. Forbindelsenes fremstilling og anvendelse beskrives.
NO20053918A 2002-03-28 2005-08-23 Aminosyrer med affinitet for alfa-2-delta-proteinet. NO20053918L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36841302P 2002-03-28 2002-03-28
PCT/IB2003/000976 WO2003082807A2 (en) 2002-03-28 2003-03-17 Amino acids with affinity for the alpha-2-delta-protein

Publications (1)

Publication Number Publication Date
NO20053918L true NO20053918L (no) 2004-12-01

Family

ID=28675482

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20044614A NO20044614L (no) 2002-03-28 2004-10-26 Aminosyrer med affinitet for alfa-2-delta-proteinet
NO20053918A NO20053918L (no) 2002-03-28 2005-08-23 Aminosyrer med affinitet for alfa-2-delta-proteinet.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20044614A NO20044614L (no) 2002-03-28 2004-10-26 Aminosyrer med affinitet for alfa-2-delta-proteinet

Country Status (42)

Country Link
US (3) US7064147B2 (no)
EP (2) EP1614675A3 (no)
JP (2) JP3831379B2 (no)
KR (2) KR100630981B1 (no)
CN (2) CN1817854A (no)
AP (1) AP1791A (no)
AR (2) AR039154A1 (no)
AU (1) AU2003208538B2 (no)
BR (1) BR0308814A (no)
CA (1) CA2480872C (no)
CR (1) CR7501A (no)
CU (1) CU23331B7 (no)
CY (1) CY1109304T1 (no)
DE (1) DE60328469D1 (no)
DK (1) DK1492761T3 (no)
EA (2) EA008709B1 (no)
EC (1) ECSP045319A (no)
ES (1) ES2327910T3 (no)
GE (2) GEP20074123B (no)
GT (2) GT200300072A (no)
HR (2) HRP20040891A2 (no)
IL (2) IL164110A0 (no)
IS (2) IS7451A (no)
MA (1) MA27188A1 (no)
MX (1) MXPA04009373A (no)
MY (1) MY131424A (no)
NI (1) NI200300043A (no)
NO (2) NO20044614L (no)
NZ (2) NZ535364A (no)
OA (1) OA12795A (no)
PA (1) PA8570001A1 (no)
PE (1) PE20040349A1 (no)
PL (1) PL209750B1 (no)
PT (1) PT1492761E (no)
RS (2) RS20050667A (no)
SI (1) SI1492761T1 (no)
TN (1) TNSN04186A1 (no)
TW (1) TWI225864B (no)
UA (2) UA80018C2 (no)
UY (1) UY27738A1 (no)
WO (1) WO2003082807A2 (no)
ZA (1) ZA200407536B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129693A1 (de) * 2001-06-22 2003-01-02 Jan Loock Verfahren zur extrakorporalen qualitativen und/oder quantitativen Erfassung neurotoxischer Substanzen im Blutplasma eines Individuums
NI200300043A (es) * 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
EP1680125A1 (en) * 2003-07-02 2006-07-19 Warner-Lambert Company LLC Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
AP2006003544A0 (en) 2003-09-25 2006-04-30 Warner Lambert Co Amino acids with affinity for the alpha2delta-protein.
CA2539976A1 (en) 2003-09-25 2005-04-07 Warner-Lambert Company Llc Therapeutic beta aminoacids
BRPI0508615A (pt) * 2004-03-12 2007-07-31 Warner Lambert Co lingandos de bisfosfina c1-simétrica e seu emprego na sìntese assimétrica de pregabalina
EP1768952A2 (en) * 2004-07-09 2007-04-04 Warner-Lambert Company LLC Preparation of beta-amino acids having affinity for the alpha-2-delta protein
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
MX2007011778A (es) * 2005-03-24 2007-10-18 Pharmacia & Upjohn Co Llc Preparacion de aminoacidos beta opticamente puros que tienen afinidad por la proteina alfa-2-delta.
WO2007052134A1 (en) * 2005-11-04 2007-05-10 Pfizer Limited (2s)-2-aminomethyl-5-ethyl heptanoic acid its pharmaceutical use
CA2629896A1 (en) * 2005-11-17 2007-05-24 Pfizer Limited Isocystene derivatives for the treatment of pain
US20090069427A1 (en) * 2006-03-06 2009-03-12 Pfizer Inc. Alpha-2-delta ligands for non-restorative sleep
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
PT2710005T (pt) 2011-05-17 2016-11-16 Principia Biopharma Inc Inibidores de tirosina-quinase
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
JP6068451B2 (ja) 2011-05-17 2017-01-25 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア キナーゼ阻害剤
CN103164756A (zh) * 2011-12-12 2013-06-19 苏州艾隆科技有限公司 贵重药品的管理方法及其系统
PT2892900T (pt) 2012-09-10 2017-11-06 Principia Biopharma Inc Compostos de pirazolopirimidina como inibidores de cinase
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
PT3107544T (pt) 2014-02-21 2021-01-05 Principia Biopharma Inc Sais e forma sólida de um inibidor de btk
CA2970723C (en) 2014-12-18 2023-09-05 Principia Biopharma Inc. Treatment of pemphigus
EP3313839A1 (en) 2015-06-24 2018-05-02 Principia Biopharma Inc. Tyrosine kinase inhibitors
IL293621B2 (en) 2016-06-29 2023-09-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile
CA3154257A1 (en) 2019-10-14 2021-04-22 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
AU2021209884A1 (en) 2020-01-22 2022-09-15 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2025078915A1 (en) * 2023-10-12 2025-04-17 Siemens Healthcare Diagnostics Inc. Pregabalin haptens, immunogens, and protein conjugates and methods of production and use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1377736A (fr) * 1962-12-21 1964-11-06 Hoffmann La Roche Procédé pour la préparation d'acides amino-carboxyliques
FR1377366A (fr) 1963-08-19 1964-11-06 Dispositif de protection de sécurité pour appareils électriques
KR880007441A (ko) * 1986-12-11 1988-08-27 알렌 제이.스피겔 스피로-치환된 글루타르아미드 이뇨제
WO1991009840A1 (en) 1989-12-22 1991-07-11 Schering Corporation Mercaptocycloacyl aminoacid endopeptidase inhibitors
US5614498A (en) 1990-06-07 1997-03-25 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic substance
US5011066A (en) * 1990-07-27 1991-04-30 Motorola, Inc. Enhanced collapse solder interconnection
US5239113A (en) 1991-10-15 1993-08-24 Monsanto Company Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof
EP0561758A3 (en) 1992-03-18 1995-04-05 Monsanto Co Method of preparing optically active homo-beta-amino acids
US5578606A (en) * 1992-10-30 1996-11-26 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors
AU684878B2 (en) 1993-11-24 1998-01-08 Merck & Co., Inc. Compounds and the use thereof to promote the release of growth hormone(s)
AU700579B2 (en) 1993-12-12 1999-01-07 Agrogene Ltd A novel method to protect plants from fungal infection
US5472830A (en) 1994-04-18 1995-12-05 Ocg Microelectronic Materials, Inc. Non-corrosion photoresist stripping composition
WO1998002410A1 (en) 1996-07-12 1998-01-22 G.D. Searle & Co. Asymetric synthesis of chiral beta-amino acids
DE69737719D1 (de) * 1996-10-23 2007-06-21 Warner Lambert Co Substituierte gamma-aminobuttersäurederivate als arzneimittel
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
GB2323594A (en) 1997-03-25 1998-09-30 Victor Martin 2-amino-alkanoic acid derivatives, 2-amino alcohols and diamines
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
US6011066A (en) 1998-02-02 2000-01-04 Veterans General Hospital-Taipei Method for treating septic shock
DE69925268T2 (de) 1998-03-16 2006-03-23 Cytovia, Inc., San Diego Dipeptid-Caspase-Inhibitoren und deren Verwendung
EP1013769A1 (en) 1998-12-22 2000-06-28 Dsm N.V. Process for the enzymatic preparation of amino acid derivatives with enhanced optical purity
FR2791982B1 (fr) 1999-04-06 2002-12-27 Inst Nat Sante Rech Med Inhibiteurs de lta4 hydrolase et leurs applications therapeutiques.
ES2317839T3 (es) * 1999-06-10 2009-05-01 Warner-Lambert Company Llc Acidos 3-propil gamma-aminobutiricos monosustituidos.
CA2408246A1 (en) * 2000-05-16 2001-11-22 Warner-Lambert Company Cell line for the expression of an .alpha.2.delta.2 calcium channel subunit
EP1282594A1 (en) 2000-05-17 2003-02-12 Medivir UK Ltd Branched amino acids
WO2002022568A1 (de) 2000-09-14 2002-03-21 Grünenthal GmbH β-THIO-AMINOSÄUREN
DE10048715A1 (de) 2000-09-30 2004-05-19 Grünenthal GmbH Verwendung von Aminosäure zur Behandlung von Schmerz
CA2440834A1 (en) * 2001-03-13 2002-09-19 Queen's University At Kingston Anti-epileptogenic agents
NI200300043A (es) * 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
CN1228312C (zh) * 2002-12-27 2005-11-23 中国科学院化学研究所 以酮为原料合成β—氨基酸的方法

Also Published As

Publication number Publication date
US20050272783A1 (en) 2005-12-08
CN1653036A (zh) 2005-08-10
WO2003082807A2 (en) 2003-10-09
CA2480872C (en) 2011-02-15
DK1492761T3 (da) 2009-09-28
JP3857714B2 (ja) 2006-12-13
GEP20074123B (en) 2007-06-11
KR100694719B1 (ko) 2007-03-16
PT1492761E (pt) 2009-09-03
PE20040349A1 (es) 2004-06-19
UA80018C2 (en) 2007-08-10
ECSP045319A (es) 2004-11-26
KR100630981B1 (ko) 2006-10-04
NZ541320A (en) 2007-01-26
ES2327910T3 (es) 2009-11-05
GEP20084298B (en) 2008-01-25
CN100462351C (zh) 2009-02-18
CY1109304T1 (el) 2014-07-02
HRP20050764A2 (en) 2006-02-28
SI1492761T1 (sl) 2009-12-31
PL373363A1 (en) 2005-08-22
PA8570001A1 (es) 2003-12-10
EA008709B1 (ru) 2007-06-29
EA200501497A1 (ru) 2006-06-30
EP1492761A2 (en) 2005-01-05
MY131424A (en) 2007-08-30
GT200300072AA (es) 2006-08-23
HK1076627A1 (zh) 2006-01-20
RS20050667A (sr) 2007-02-05
EP1614675A3 (en) 2006-03-29
WO2003082807A3 (en) 2003-12-24
CN1817854A (zh) 2006-08-16
US20030195251A1 (en) 2003-10-16
DE60328469D1 (de) 2009-09-03
JP2006028189A (ja) 2006-02-02
NZ535364A (en) 2007-05-31
JP3831379B2 (ja) 2006-10-11
TW200305576A (en) 2003-11-01
EP1614675A2 (en) 2006-01-11
IS7951A (is) 2005-07-21
AU2003208538B2 (en) 2009-07-16
NI200300043A (es) 2003-11-05
US7064147B2 (en) 2006-06-20
NO20044614L (no) 2004-12-01
CR7501A (es) 2005-01-24
UY27738A1 (es) 2003-10-31
RS83604A (sr) 2007-02-05
IL169820A0 (en) 2007-07-04
UA80116C2 (en) 2007-08-27
OA12795A (en) 2006-07-18
AP2004003144A0 (en) 2004-09-30
US7517909B2 (en) 2009-04-14
CU23331B7 (es) 2008-12-24
US20060154972A1 (en) 2006-07-13
AP1791A (en) 2007-10-15
EA200401127A1 (ru) 2005-06-30
JP2005521723A (ja) 2005-07-21
BR0308814A (pt) 2005-01-04
CA2480872A1 (en) 2003-10-09
EP1492761B1 (en) 2009-07-22
GT200300072A (es) 2004-01-21
MXPA04009373A (es) 2005-01-25
HRP20040891A2 (en) 2004-12-31
TNSN04186A1 (fr) 2007-03-12
PL209750B1 (pl) 2011-10-31
IS7451A (is) 2004-09-16
IL164110A0 (en) 2005-12-18
KR20040094882A (ko) 2004-11-10
TWI225864B (en) 2005-01-01
AR050261A2 (es) 2006-10-11
MA27188A1 (fr) 2005-01-03
ZA200407536B (en) 2006-01-25
AR039154A1 (es) 2005-02-09
KR20060007446A (ko) 2006-01-24
AU2003208538A1 (en) 2003-10-13

Similar Documents

Publication Publication Date Title
NO20053918L (no) Aminosyrer med affinitet for alfa-2-delta-proteinet.
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
BR0312785A (pt) Tratamento de desordens relacionadas a tnf(alfa)
WO2000055125A3 (en) N-cyanomethyl amides as protease inhibitors
SE9800836D0 (sv) New Compounds
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
WO2003082853A8 (en) New compounds
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
ATE376832T1 (de) Verzögert freisetzende formulierungen von oxymorphon
NO20032111L (no) Nye medikamentblandinger basert pa tiotropium-salter og pa salmeterol-salter
WO2001068645A3 (en) N-cyanomethylcarboxamides and their use as protease inhibitors
NO20082989L (no) Fremstiling av gamma-aminosyrer som har affinitet for alfa-2-deltaproteinet
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20061801L (no) Fremgangsmater for anvendelse av aminosyter med affinitet for alfa-2-deltaproteinet
NO20061812L (no) Aminosyrer med affiniter for alfa2delta-proteinet
WO2004002491A8 (en) Morpholine and tetrahydropyran drivatives and their use as cathepsin inhibitors
AU2002332488A8 (en) R-bambuterol, its preparation and therapeutic uses
TW200612922A (en) Inhibitors of hsp90
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
WO2002017905A3 (en) Treatment of burns
NO20065643L (no) Fremstilling av beta-aminosyrer som har affinitet for proteinet alfa-2-delta
BRPI0513028A (pt) preparação de beta-aminoácidos tendo afinidade para a proteìna alfa-2-delta
ITMI20022594A1 (it) Combinazione terapeutica per la cura dell'ipertensione.
SG143979A1 (en) Novel compounds and compositions as cathepsin inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application